▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Marijuana buds and CBD oil

Apr 12, 2019 by Keith Speights

Aurora Cannabis Strikes Oil in Germany, and Higher Revenue and Profit Margins Should Be on the Way

The Canadian marijuana producer is now selling cannabis oils in Europe. It's a bigger deal than you might think.

Soaring man and chart

Apr 12, 2019 by Keith Speights

Why Akebia Therapeutics Is Soaring Today

Great news from two late-stage studies lit a fire under the biopharmaceutical stock.

Man behind stock chart

Apr 12, 2019 by Keith Speights

3 Stocks That Could Double Your Money

Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.

Marijuana leaves and money

Apr 12, 2019 by Keith Speights

Why 1 Top Analyst Thinks Aurora Cannabis Beats Canopy Growth As the Best Marijuana Stock on the Market

Canopy Growth might be bigger when it comes to market cap. But a Cowen analyst thinks Aurora Cannabis is the better marijuana stock right now.

Marijuana leaves with shadow of maple leaf

Apr 12, 2019 by Keith Speights

Looking to Buy CannTrust Holdings? 5 Things You Should Know First

This Canadian marijuana stock is flying high. Here's what you'll want to know before jumping on the bandwagon.

Scientist looking through microscope

Apr 12, 2019 by Keith Speights

A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit

Cannabinoids that don't require cannabis just might make these stocks huge winners in the future.

Marijuana with line chart

Apr 12, 2019 by Keith Speights

Aurora Cannabis, Canopy Growth, or Tilray: Which Stock Will Be the Amazon of the Marijuana Boom?

Amazon prospered while most dot-com era companies flopped. Could one of these top marijuana stocks be a similar success story?

Marijuana leaves with shadow of dollar sign

Apr 12, 2019 by Keith Speights

Better Marijuana Stock: HEXO vs. Innovative Industrial Properties

Which stock wins in a matchup between a fast-growing Canadian marijuana producer and an even faster-growing U.S. cannabis-focused REIT?

Hands holding $100 bills and a cannabis leaf

Apr 12, 2019 by Keith Speights

Is OrganiGram Holdings a Buy?

There's a lot to like with this high-flying marijuana stock. But some reasons for concern, too.

Weighing the options

Apr 12, 2019 by Keith Speights

Better Buy: Abbott Laboratories vs. Johnson & Johnson

Which stock wins in a matchup between these two healthcare giants?

Magnifying glass with DNA helix

Apr 12, 2019 by Keith Speights

Is Illumina a Buy?

It's the biggest winner in gene sequencing ever. But can Illumina maintain its dominance?

Tug of war

Apr 12, 2019 by Keith Speights

Here's Canopy Growth's Top Rival (Hint: It Isn't Aurora Cannabis, Cronos Group, or Tilray)

And it could take a long time for Canopy Growth to beat its most significant challenger.

Illinois sign with marijuana leaf

Apr 12, 2019 by Keith Speights

Here's the Next Likely Multibillion-Dollar Marijuana Market

The Land of Lincoln could be the land of marijuana money -- and lots of it.

Search bar in front of hands on laptop keyboard

Apr 12, 2019 by Keith Speights

The Top Stock Warren Buffett Should Buy but Hasn't Yet

There's an Applesque stock that's ripe for the picking for the legendary investor.

Yield with coins

Apr 12, 2019 by Keith Speights

4 Stocks to Buy With Dividends Yielding More Than 4%

High dividend yields. Solid business models. These stocks have exactly what income-seeking investors want.

Man facing arrows

Apr 12, 2019 by Keith Speights

Better Buy: Align Technology vs. Intuitive Surgical

These two companies have been super-successful in their niche markets. But which is the better pick for long-term investors?

Marijuana close-up in greenhouse

Apr 11, 2019 by Keith Speights

Better Marijuana Stock: Aurora Cannabis vs. Green Thumb Industries

Which stock wins in a battle between a big Canadian marijuana producer and an up-and-coming U.S. marijuana business?

Test tube and question mark

Apr 12, 2019 by Keith Speights

Why AcelRx Pharmaceuticals Stock Is Sinking Today

Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.

Pipettes

Apr 11, 2019 by Keith Speights

Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.

Health insurance application on tablet

Apr 11, 2019 by Keith Speights

Why Health Insurance Innovations Is Jumping Today

Great Q4 results and a bullish outlook for 2019 caused the stock to take off.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services